2cureX receives Notice of Allowance from the United States Patent Office

March 28 | 2019
2cureX AB (“2cureX”) is pleased to announce the expansion of the patent protection of its key product, IndiTreat® to USA. As earlier communicated, 2cureX was granted the European patent No. 3164709 “Identifying compounds modifying a cellular phenotype” in August 2018. 2cureX now receives the same protection in the US market through allowance of US patent application no. 15/321,888. The US patent will be in force until at least July 2035. The patent is currently also being prosecuted in territories outside Europe and USA.

2cureX has developed and is clinically validating the IndiTreat® test that uniquely matches the individual cancer patient with an effective medical treatment. IndiTreat® generates thousands of small micro-tumours (tumoroids) from a small tissue sample obtained from the patient’s primary tumour or metastasis. 2cureX’s patents protect the application of the tumoroid technology in a clinical setting where available mono- and combination therapies are tested on the individual patient’s tumoroids. The beauty of IndiTreat® is that the patient will be put on the right treatment immediately after the test has been conducted.

IndiTreat® helps oncology caregivers determine to which cancer treatment the patient is sensitive and to which the patient is resistant. IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer. Positive interim data in colorectal cancer was obtained in February 2019.

“It is really rewarding to see that our original idea of constructing an individual treatment test now is acknowledged in both Europe and the US” says Grith Hagel, Inventor and Head of Development at 2cureX and she continues; “we are constantly expanding the scope of IndiTreat® to new cancer entities and even to preventive cancer medicine. The solid patent protection is important when establishing new partnerships with clinical institutions.”

2cureX is in the process of preparing the launch of IndiTreat® on the European market” says Maarten van der Linden, Chief Business Officer and he continues; “that we now obtained strong patent protection in the US for the IndiTreat® test strengthens our position in commercial discussions and attractiveness of 2cureX for potential partners to launch IndiTreat® in new markets, like the US”

Certified Adviser

Sedermera Fondkommission
E-mail: ca@sedermera.se
Phone: +46 40 615 14 15

For more information about 2cureX:

Ole Thastrup, CEO          
E-mail: ot@2cureX.com
Phone: +45 22 11 53 99                
URL: www.2curex.com

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 28th, 2019.

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).